Pfizer's Practical Predator: CEO Ian Read
This article was originally published in The Pink Sheet Daily
Executive Summary
The naturalized US citizen's M&A method means mixing money and medicines in a tax-efficient manner. Interactive timeline tracks major acquisitions and divestitures during Read's tenure.
You may also be interested in...
Bigger And Smaller? Pfizer Pursues AstraZeneca But Hasn’t Given Up On A Split
A Pfizer break up is still an option even if the company completes a mega-merger with AstraZeneca, CEO Ian Read said May 5. The company’s first quarter sales and earnings results highlighted how important completing a transaction could be for the company, with sales down 9% and earnings down 15%.
Reading Into Pfizer's Changes: First Steps For New CEO
Pfizer Inc.'s new CEO Ian Read came out of the gates strong during the company's year-end financial presentation Feb. 1, with news that investors greeted warmly: additional, unexpected cuts to R&D and further R&D reorganization, a $5 billion share buyback program, and assurance that all options are on the table when it comes to Pfizer's diversified portfolio of businesses.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.